Physician profile
Steven D Freeman
NPI 1396737425
$2,968.30
in general payments reported to CMS, 2019-2025
21 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $352 · 2021: $126 · 2022: $410 · 2023: $224 · 2024: $478 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $871.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $531.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $300.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $268.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $168.47 | 2019-2025 | Shingrix, Arexvy, Penmenvy |
| Exact Sciences Corporation | $154.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.58 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.83 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $68.92 | 2019-2022 | |
| Amarin Pharma, INC. | $52.44 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.03 | 2022 | |
| Corium, LLC | $48.42 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $47.72 | 2019 | |
| Abbott Laboratories | $46.60 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $35.44 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $34.75 | 2023-2024 | Zilretta, Iovera, Exparel |
| Amgen INC. | $27.80 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $25.66 | 2019 | |
| Dexcom, INC. | $20.96 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $18.26 | 2020 | |
| Abbvie INC. | $16.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.